Quick Answer
IceCure Medical Ltd. reported Total Revenue of $3.38 million for fiscal year 2025.
IceCure Medical Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.38M +2.7% |
$3.29M +1.9% |
$3.23M +4.7% |
$3.08M -25.4% |
$4.14M +7.0% |
$3.87M |
| Net Income | -$15.06M +1.7% |
-$15.32M -4.5% |
-$14.65M +13.7% |
-$16.98M -71.6% |
-$9.89M -165.3% |
-$3.73M |
| Diluted EPS | $0.24 -20.0% |
$0.30 -6.3% |
$0.32 -30.4% |
$0.46 +31.4% |
$0.35 +59.1% |
$0.22 |
| Total Assets | $13.89M +10.4% |
$12.58M -23.4% |
$16.41M -45.6% |
$30.19M -6.5% |
$32.28M +215.3% |
$10.24M |
| Cash and Equivalents | $8.90M +17.6% |
$7.56M -28.2% |
$10.53M -55.5% |
$23.66M -7.7% |
$25.62M +631.6% |
$3.50M |
| Long-Term Debt | $13.0K -91.9% |
$161.0K | — | — | — | — |
| Stockholders Equity | $9.05M +31.2% |
$6.90M -43.3% |
$12.16M -52.2% |
$25.42M -5.7% |
$26.96M +377.3% |
$5.65M +71.6% |
| R&D Expense | $7.43M +4.7% |
$7.10M -14.2% |
$8.27M -9.3% |
$9.12M +55.2% |
$5.88M +54.3% |
$3.81M |
| Operating Income | -$15.09M +3.8% |
-$15.70M -0.8% |
-$15.58M +6.9% |
-$16.74M -72.1% |
-$9.72M -134.8% |
-$4.14M |
| Gross Profit | $1.23M -15.5% |
$1.45M +11.6% |
$1.30M -10.0% |
$1.45M -34.2% |
$2.19M -10.2% |
$2.44M |
| Shares Outstanding | 73.12M +29.3% |
56.57M +23.7% |
45.73M +0.2% |
45.62M +27.5% |
35.78M +77.0% |
20.22M |
- IceCure Medical Ltd. reported Total Revenue of $3.38 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +2.7% in Total Revenue compared to the prior fiscal year.
- IceCure Medical Ltd. reported Net Income of -$15.06 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +1.7% in Net Income compared to the prior fiscal year.
- IceCure Medical Ltd. reported Diluted EPS of $0.24 per share for fiscal year 2025.
- IceCure Medical Ltd. showed a decrease of -20.0% in Diluted EPS compared to the prior fiscal year.
- IceCure Medical Ltd. reported Total Assets of $13.89 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +10.4% in Total Assets compared to the prior fiscal year.
- IceCure Medical Ltd. reported Cash and Equivalents of $8.90 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +17.6% in Cash and Equivalents compared to the prior fiscal year.
- IceCure Medical Ltd. reported Long-Term Debt of $13.0 thousand for fiscal year 2025.
- IceCure Medical Ltd. showed a decrease of -91.9% in Long-Term Debt compared to the prior fiscal year.
- IceCure Medical Ltd. reported Stockholders Equity of $9.05 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +31.2% in Stockholders Equity compared to the prior fiscal year.
- IceCure Medical Ltd. reported R&D Expense of $7.43 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +4.7% in R&D Expense compared to the prior fiscal year.
- IceCure Medical Ltd. reported Operating Income of -$15.09 million for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +3.8% in Operating Income compared to the prior fiscal year.
- IceCure Medical Ltd. reported Gross Profit of $1.23 million for fiscal year 2025.
- IceCure Medical Ltd. showed a decrease of -15.5% in Gross Profit compared to the prior fiscal year.
- IceCure Medical Ltd. reported Shares Outstanding of 73.12 million shares for fiscal year 2025.
- IceCure Medical Ltd. showed an increase of +29.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: